Her2-positive Lung Cancer Treated With Dedicated Drug
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
HER2 (erbB-2/neu) is a member of the erbB receptor tyrosine kinase family. ERBB2 gene which
encodes human epidermal growth factor 2 (HER2) is a major proliferative driver activating
downstream signaling through PI3K-AKT and MEK-ERK. HER2 overexpression or gene amplification
is associated with sensitivity to trastuzumab and lapatinib in breast cancer. Among actual
lung cancer biomarker, HER2 remains apart. HER2 involvement is known for a long time but
clinical research has been stopped for many years since the first clinical trials in
unselected patients were negative. Recently trastuzumab + pertuzumab + docetaxel has been
tested for first-line treatment of HER2-positive metastatic breast cancer (CLEOPATRA trial).
Analysis of the primary end point showed that patients who received pertuzumab, trastuzumab,
and docetaxel (pertuzumab group) had a significantly longer median progression-free survival,
as assessed by independent reviewers an did those who received placebo, trastuzumab, and
docetaxel (control group) (hazard ratio favoring the pertuzumab group, 0.62). There is thus a
strong rational for treating HER2 mutated lung cancer patient with these drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique